Nontuberculous Mycobacteria treatment Archives - DelveInsight

Nontuberculous Mycobacteria treatment

NTM infection drug pipeline
Bridging the gap: Nontuberculous mycobacterium Infections Drug Pipeline

Slowly or rapidly growing bacteria- Nontuberculous mycobacteria (NTM), might appear innocuous, however, NTM infections have a notably higher total prevalence of 3,65,273 in the 7MM, estimates Delv...


Nontuberculous Mycobacteria Infection
Lack of effective therapy: A major Nontuberculous Mycobacteria Infection Market Driver

Nontuberculous Mycobacteria (NTM) is a ubiquitous, aerobic, non-motile, acid-fast bacteria, which, when inhaled, may cause severe lung disorders. Especially common in the elderly, individuals with...


Editor's Pick
22 Healthcare Trends & Innovations to Watch in 2022 and Beyond

With the advent of new-age healthcare industry trends that are evident as of now, there...

Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021

Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did...

Analyzing the Key Trends Driving the Biosimilar Market Growth

The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a...

CAR-T Cell Therapy aka Miraculous Technology: Mapping the Market, Approved Th...

Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative pot...

Myelodysplastic Syndromes (MDS): Key Pharma Players Unveiling Updated Finding...

There has been limited progress in the approval of novel agents in MDS. It has been a l...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.